T1	Participants 779 1049	a randomized double-blind trial of gemfibrozil versus placebo in 2,531 men with coronary disease, HDL-C levels of 40 mg/dL or less (< or =1.0 mmol/L), low-density lipoprotein cholesterol levels of 140 mg/dL or less (< or =3.6 mmol/L), and a range of triglyceride values.
T2	Participants 1415 1494	1,981 individuals, of whom 399 individuals (20.2%) were eligible for inclusion.
